Press release
Tyrosine Kinase Inhibitors Market Key Trends and Growth Drivers in Targeted Therapy | Key Players: Bayer Corporation, F. Hoffmann-La Roche Ltd, AstraZeneca, Novartis AG
Tyrosine Kinase Inhibitors Market reached US$ 51.03 billion in 2023 and is expected to reach US$ 82.47 billion by 2031, growing at a CAGR of 6.3% during the forecast period 2024-2031.Tyrosine Kinase Inhibitors Market analysis, according to DataM Intelligence, offers more than just an overview, it investigates the underlying aspects of the sector. The study provides an overview, the research explores the hidden aspects of the sector, breaking down its intricate dynamics, charting regional dominance, spotting demand patterns, and spotting prospective breakthroughs that could influence how businesses operate in the future.
Get a Free Sample PDF copy of the report - https://datamintelligence.com/download-sample/tyrosine-kinase-inhibitors-market
The Tyrosine Kinase Inhibitors market report majorly focuses on market trends, historical growth rates, technologies, and the changing investment structure. Additionally, the report shows the latest market insights, increasing growth opportunities, business strategies, and growth plans adopted by major players. Moreover, it contains an analysis of current market dynamics, future developments, and Porter's Five Forces Analysis.
Tyrosine kinase inhibitors (TKIs) are a class of drugs that block the activity of enzymes known as tyrosine kinases. Tyrosine kinases are a type of enzyme that plays a critical role in the regulation of cell functions, including cell growth, differentiation, metabolism, and apoptosis (cell death). These enzymes are involved in signaling pathways that control how cells respond to external signals, and when dysregulated, they can lead to various diseases, including cancer.
Forecast Growth Projected:
The Global Tyrosine Kinase Inhibitors Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.
List of the Key Players in the Tyrosine Kinase Inhibitors Market:
Boehringer Ingelheim International GmbH, Bayer Corporation, F. Hoffmann-La Roche Ltd, AstraZeneca, Novartis AG, Bristol Myers Squibb, Pfizer Inc, Eli Lilly, and Company, Eisai Co., Ltd, and Takeda Pharmaceutical Company Limited among others.
Segment Covered in the Tyrosine Kinase Inhibitors Market:
➧ By Type (BCR-ABL Tyrosine Kinase Inhibitor, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors, Receptor Tyrosine Kinase Inhibitor , Non- Receptor Tyrosine Kinase Inhibitors (n RTKI's), Others)
➧ By Application (Chronic Myeloid Leukemia, Lung Cancer, Breast Cancer, Renal Cell Cancer, Others)
➧ By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others)
Key Developments
In March 2024, Takeda announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ICLUSIG (ponatinib) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.
In March 2024, Novartis AG is in discussions to secure a distribution partner for the imminent launch of Asciminib, the first-in-class treatment for chronic myeloid leukemia (CML) targeting the ABL myristoyl pocket (STAMP). Asciminib is the first tyrosine kinase inhibitor (TKI) to target the ABL1 myristoyl pocket. TKIs are frequently effective in treating CML for prolonged periods.
In February 2024, AstraZeneca's Tagrisso (osimertinib) with the addition of chemotherapy has been approved in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months vs. standard of care.
In January 2024, Novartis announced positive results from the primary analysis of ASC4FIRST, a pivotal Phase III trial comparing Scemblix(asciminib) with investigators' choice of tyrosine kinase inhibitor (TKI) treatment in newly diagnosed patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP).
In January 2024, Bristol Myers Squibb announced that the European Medicines Agency (EMA) has validated its marketing authorization application for the next-generation tyrosine kinase inhibitor (TKI) repotrectinib as a treatment for ROS1 TKI-naïve and -pretreated adult patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) and TKI-naïve and -pretreated adult and pediatric patients 12 years and older with NTRK-positive locally advanced or metastatic solid tumors.
Get this Premium Report: https://www.datamintelligence.com/buy-now-page?report=tyrosine-kinase-inhibitors-market
Regional Break out:
The global Tyrosine Kinase Inhibitors Market report focuses on six major regions: North America, South America, Europe, Asia Pacific, the Middle East, and Africa.
☞ North America - US, Canada, Mexico
☞ Europe- Germany, Russia, UK, France, Italy, Rest of Europe
☞ Asia Pacific- China, India, Japan, Australia, Rest of Asia Pacific
☞ South America- Brazil, Argentina, Colombia, Rest of South America
☞ Middle East and Africa- Saudi Arabia, UAE, Oman, Bahrain, Qatar, Kuwait, Israel
Chapter Outline:
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: key insights, key emerging trends, etc.
Chapter 3: Manufacturers competitive analysis, detailed analysis of Tyrosine Kinase Inhibitors manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 5 & 6: Revenue of Tyrosine Kinase Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: The main points and conclusions of the report.
Speak to Our Senior Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/tyrosine-kinase-inhibitors-market
Frequently asked questions:
➠ What is the global sales value, production value, consumption value, import and export of Tyrosine Kinase Inhibitors market?
➠ Who are the global key manufacturers of the Tyrosine Kinase Inhibitors Industry? How is their operating situation (capacity, production, sales, price, cost, gross, and revenue)?
➠ What are the Tyrosine Kinase Inhibitors market opportunities and threats faced by the vendors in the global Tyrosine Kinase Inhibitors Industry?
➠ Which application/end-user or product type may seek incremental growth prospects? What is the market share of each type and application?
➠ What focused approach and constraints are holding the Tyrosine Kinase Inhibitors market?
➠ What are the different sales, marketing, and distribution channels in the global industry?
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Tyrosine Kinase Inhibitors Market Key Trends and Growth Drivers in Targeted Therapy | Key Players: Bayer Corporation, F. Hoffmann-La Roche Ltd, AstraZeneca, Novartis AG here
News-ID: 3818174 • Views: …
More Releases from DataM intelligence 4 Market Research LLP

Chelating Agents Market Set for Rapid Expansion with CAGR of 4.2% by 2024-2031 | …
The Global Chelating Agents Market is estimated grow at a CAGR of 4.2% during the forecast period (2024-2031).
The Chelating Agents market report provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. With a commitment to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Leveraging a combination of qualitative and quantitative research methods, the company offers comprehensive…

Last Mile Delivery Market is Projected to reach US$ 311.31 Billion by 2031, Grow …
Global Last-Mile Delivery Market reached US$ 151.87 billion in 2023 and is expected to reach US$ 311.31 billion by 2031, growing with a CAGR of 9.62% during the forecast period 2024-2031.
The Last Mile Delivery market report provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. With a commitment to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the…

Amyotrophic Lateral Sclerosis (ALS) Market Future Prospects, Growth, SWOT Analys …
The Global Amyotrophic Lateral Sclerosis Market size reached USD 0.7 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 1.0 billion by 2031. The global amyotrophic lateral sclerosis market is expected to exhibit a CAGR of 5.1% during the forecast period (2024-2031).
The Amyotrophic Lateral Sclerosis (ALS) market report provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. With a…

Assisted Reproductive Technology Market is Expected to Exhibit a CAGR of 6.1% Du …
The global assisted reproductive technology market reached USD 33.8 billion in 2022 and is expected to witness lucrative growth by reaching up to USD 53.7 billion by 2030. The global assisted reproductive technology market is expected to exhibit a CAGR of 6.1% during the forecast period (2024-2031).
The Assisted Reproductive Technology market report provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. With a commitment to…
More Releases for Tyrosine
Global Tyrosine Market 2015-2025 | Growing Opportunities and Trends in Tyrosine …
The Market Research Store has added the latest report on the Global Tyrosine Market which includes the historical data from 2015 to 2019 and has also precisely forecasted data from 2020 to 2025. The global Tyrosine market anticipates to showcase market value in terms of USD Million during the forecast period 2020 to 2025. According the research analyst the market will witness a steady growth during the coming years.
Get Sample…
Tyrosine Kinase Inhibitors - Pipeline Insights 2017
The “Tyrosine kinase Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of tyrosine kinase inhibitor drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential Akt inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent,…
Tyrosine Kinase Inhibitors - Pipeline Insights 2017
The “Tyrosine kinase Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of tyrosine kinase inhibitor drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential Akt inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent,…
Research Study on Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyro …
Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) comprises nearly 15 molecules. Of these, nearly 9 are developed by companies and the rest are developed by universities. Many molecules developed by companies are in various stages. The situation is more or less similar for molecules developed by universities. A new research study added to the…
Research Study on Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyro …
Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) comprises nearly 15 molecules. Of these, nearly 9 are developed by companies and the rest are developed by universities. Many molecules developed by companies are in various stages. The situation is more or less similar for molecules developed by universities. A new research study added to the…
Tyrosine Kinase Inhibitors - Pipeline Insights 2017
The “Tyrosine kinase Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of tyrosine kinase inhibitor drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential Akt inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent,…